Sager C, Sanmartino M, Burek C, et al. - Researchers investigated the efficacy and safety of mirabegron as adjuvant treatment for patients with refractory neurogenic bladder dysfunction. They studied 37 patients under 18 years of age who underwent Mirabegron. Criteria for inclusion comprised: cases with neurogenic bladder who were under clean intermittent catheterization (CIC) programs and refractory to oral oxybutynin (Group A) and/or onabotulinumtoxinA (Group B). Outcomes revealed significant improvement in the clinical and urodynamic parameters in correlation with Mirabegron treatment. Both groups had a significant rise in bladder capacity and a significant reduction in end-filling detrusor pressure. Attenuation in the intensity of overactivity was noted. According to the records of the voiding diary, administration of Mirabegron led over 70% of the incontinent patients to become dry. No adverse effects were identified.

.